2 news items
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
CRVS
6 May 24
, that were measurable by CT scan or by Modified Severity-Weighted Assessment Tool (mSWAT) for patients with cutaneous involvement. PTCL-NOS, peripheral T cell
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
CRVS
9 Apr 24
Assessment, reduction in itch and various cytokine biomarkers. Corvus and a data monitoring committee will be able to monitor the data from the trial
- Prev
- 1
- Next